The better understanding of the mechanism in which the immune system responds to the developing cancer provided the outcome in a new era in cancer immunotherapy. The tumor suppressive effect on the immune system is caused by negative T cell receptor signaling that abrogate immunity against the cancer cells. Novel monoclonal antibodies that target co-inhibitory receptors on T cells block the tumor induced inhibition of the immune system and enable the immune system to eradicate the tumors. The development of such antibodies started twenty years ago by the preparation of a monoclonal antibody termed BAT. A single administration of the antibody to tumor bearing mice resulted in striking anti tumor activity that was mediated by the lymphocytes. These studies provided a basis for the new era of cancer immunotherapy. The present review summarizes twenty years to the discovery of monoclonal antibodies harnessing the immune system to eradicate tumors.
INTRODUCTION
The interaction between cancer cells and the host immune system exhibits an intriguing and dynamic clash for life. Tumor progression under immune pressure includes three major motions: elimination, equilibrium and escape [1, 2] . In the first phase, the innate and adaptive immune system abolishes nascent tumor cells (immune surveillance) [3] . If not all cancer cells are eliminated, the second phase is the equilibrium between cancer and the immune system, in which the tumor remains dormant temporarily. The interaction between cancer cells and the host immune system induces inhibitory immune reactions that result in tumor escape and the development of clinically evident disease [1, [4] [5] [6] [7] .
In the past, several approaches have been used to harness and stimulate the immune system to fight cancer such as vaccination of cancer patients with vaccine against tuberculosis BCG [8] [9] [10] that induced cellular immune responses. Stimulation of cellular immunity was also experimented by the administration of large numbers of T cells from tumor-infiltrating lymphocytes or engineered T cells to express receptors for specific tumor-associated antigens (TAA) [11, 12] . Immunization was further studied with peptide-pulsed or tumor lysate-pulsed dendritic cells [13, 14] and cytokine-mediated immune therapy [7, 15] .
However, the success of such activation of the immune system to fight cancer remained poor and was unsatisfactory for clinical immunotherapy [16, 17] .
In the last 20 years immunotherapy has been undergoing an exclusive progress resulting from new understanding of the mechanism in which the immune system responds to the developing cancer [18, 19] . The developing cancer induces a state of "anergy" in which the immune system is not activated to fight the tumor. The new cancer immunotherapy, different from the previous approach, is to activate the immune system by releasing it from the suppressive effect of the developing cancer [20] [21] [22] .
In order to achieve clinical proof of this concept, this approach included the development of novel monoclonal antibodies that block the tumor-induced inhibition of the immune system thus enabling the immune system to eradicate tumors.
NEGATIVE T CELL RECEPTOR SIGNALING THAT ABROGATE IMMUNITY AGAINST CANCER CELLS
Several activation signals are required to induce the OPEN ACCESS cellular immunity. The first signal for T cell activation requires the major histocompatibility complex (MHC) recognition on the tumor cell by the T cell CD3 receptor [23] . However MHC binding by itself is insufficient for producing a T cell response. Lack of further stimulatory signals will send the immune response into "anergy" [22, 24] . A second signal is necessary in order to continue the immune response. This signal can come from co-stimulatory molecules. One such source of a second signals is the T cell binding receptors peripheral membrane proteins of the B7 family [22, 25, 26] . The B7 family of cosignaling molecules is expressed on the surface of antigen presenting cells (APC) and also on T lymphocytes. These co-signaling molecules provide significant positive signals that stimulate T-cell growth, up-regulate cytokine production and promote T-cell differentiation. In parallel, they also provide negative co-signaling molecules that contribute for the impediment of immunologic tolerance or attenuate T-cell responses [22] [23] [24] [25] [26] [27] [28] .
A primary co-stimulatory signal is delivered through the binding of the T cell receptor CD28 to its ligands B7-1 (CD80) or B7-2 (CD86).
An inhibitory T cell receptor CTLA-4 (CD152) binds the same B7-1 or B7-2 ligands with twenty-times greater affinity. As a result, the T cell is blocked from receiving the B7 protein signal by CD28 co-stimulatory molecule and is therefore not activated. Binding of the B7 to CTLA-4 causes inhibition (or "anergy") of the T-cell activity [22, 29, 30] .
A second recently defined inhibitory receptor, whose expression can be induced primarily on the cell surface of activated T cells is the programmed death-1 receptor (PD-1) [31] . PD1 is a 50 -55 kDa trans-membrane receptor that was identified in a T cell line undergoing activation induced cell death [31] . PD-1 was also found to be highly expressed on induced regulatory T cells (iTregs) suggesting an additional mechanism for immunosuppression in a tumor microenvironment [32] .
Monoclonal antibodies directed against such tumor immune negative co-stimulatory receptors, suggested a promising novel approach for anticancer immunotherapy based on promoting immune responses against cancer as well as breaking up tumor resistance and dormancy.
THE USE OF ANTIBODIES IN CANCER THERAPY
The use of monoclonal antibodies in cancer therapy was based for many years on antibodies that target determinants on the cancer cell itself. Since determinants on cancer cells were not steady due to tumor alterations, that approach was found to be insufficient in cancer therapy [33] .
The new immunotherapy uses antibodies targeting co-inhibitory receptors on T cells that block the tumorinduced inhibition of the immune system. This enhances the immune function against the tumor, leading to successful clinical trials currently determining eradication of tumors.
The development of such monoclonal antibodies started twenty years ago. A monoclonal antibody prepared against cell membranes of Daudi cells was investigated. This antibody, termed BAT, was found to induce T cell proliferation and increase cytotolytic activity in human peripheral blood cells [34] . Administration of BAT monoclonal antibody to experimental tumor bearing mice demonstrated striking anti tumor activities in a wide range of both murine and human tumors [35] [36] [37] [38] [39] .
It was for the first time that antitumor activity was achieved by adoptive transfer of lymphocytes from BAT treated mice to tumor bearing recipients. The transfer of lymphocytes that induced tumor regression demonstrated that the lymphocytes alone mediated the anti-tumor activity. Mice that were cured of tumor were also partially resistant to further challenge with the tumor [35] . The anti tumor activity mediated by lymphocytes was also demonstrated in SCID mice that were engrafted with human lymphocytes against human melanoma [36] .
The mechanism of action of BAT determined that NK or T cells mediated the antitumor effect of BAT [35] and the primary cellular target for BAT in human peripheral blood cells were CD4 + T cells that stimulated the secretion of IFN-γ [40] . The local secretion of IFN-γ induces an anti-tumor response by recruitment of host immune cells to the tumor resulting in a successful host anti-tumor immune response. Stimulation of CD4 + T cells in association with NK cells produces a cascade of events leading to the development of a T h 0 or T h 1 response or to a shift of a T h 2 response towards a T h 1 or T h 0 profile. Assuming that NK cells can influence CD4 + and that CD4 + T cells are able to facilitate the generation of CD8 + cytotoxic T lymphocytes (CTL) through their elaboration of cytokines, the interaction between NK cells, activated CD4 + T cells and CD8 + CTL precursors contributes to the induction of effector CTL [40] .
The potential clinical use of BAT monoclonal antibody was demonstrated against a wide range of tumors, confirming the inhibition of the "anergy" induced by the tumor on the immune system.
A single injection of BAT resulted in the reduction of leukemia/lymphoma cells. Anti-tumor effect was also obtained when animals were injected with splenocytes from BAT-treated donor mice [37] . Anti tumor effect of the humanized form of BAT, termed CT011, was demonstrated against human colorectal carcinoma (CRC) in nude mice with liver metastases that were replaced by lymphocytes [38] .
The anti-tumor activity of BAT provided the basis for its potential use in human immunotherapy. It was demonstrated that a single administration of 0.2 to 6.0 mg/kg of CT-011 is safe and well tolerated in patients with advanced hematologic malignancies. The observed clinical benefits may be related to durable tumor-specific immune response that is induced by CT-011 [41] . A phase II clinical study evaluated the safety and efficacy of CT-011 administered at the dose level of 1.5 mg/kg in diffuse large B-cell lymphoma following autologous bone marrow transplantation. CT-011 dose was chosen based on the pharmacokinetic analysis done in this phase I study as well as on comparability to efficacy and pharmacokinetic parameters obtained in studies conducted in animal models.
CONCLUSION
These studies provided the basis for the new era of cancer immunotherapy that uses monoclonal antibodies that target CTLA4 and PD-1 thus enable the immune system to eradicate the tumor [42] . Nevertheless it seems that other receptors with similar properties are expressed by T cells and may be also recruited to immunotherapy to improve cancer treatment in the future.
